Core Viewpoint - Hims & Hers Health, Inc. is facing two securities class action lawsuits following the termination of its collaboration with Novo Nordisk due to concerns over deceptive marketing practices related to the weight loss drug Wegovy® [1][2][4]. Group 1: Lawsuits and Allegations - The lawsuits, filed on June 25, 2025, seek to represent investors who acquired Hims & Hers securities between April 29, 2025, and June 23, 2025 [1][3]. - Allegations include that Hims & Hers made false and misleading statements and failed to disclose critical information regarding the safety of its products and the legality of its marketing practices [4][5]. - The termination of the collaboration with Novo Nordisk was announced on June 23, 2025, citing concerns over illegal mass compounding and deceptive marketing practices that jeopardized patient safety [5]. Group 2: Impact on Share Price - Following the announcement of the termination, Hims & Hers shares experienced a significant decline, crashing by 30% [2]. Group 3: Investigation and Legal Support - Hagens Berman, a national shareholders rights firm, is investigating the claims and encourages affected investors to report their losses [3][6]. - The firm is also seeking information from individuals who may assist in the investigation, highlighting the potential for whistleblower rewards under the SEC Whistleblower program [6].

Core Viewpoint - Hims & Hers Health's stock has experienced a significant decline following the termination of its sales partnership with Novo Nordisk, amid allegations of improper practices related to the sale of compounded semaglutide, a key weight loss drug [2][7][13]. Group 1: Company Overview - Hims & Hers Health has leveraged the popularity of weight loss drugs, particularly GLP-1 agonists like Wegovy, to become a top market performer, with its stock rising nearly 100% over the past year before the recent downturn [2][4]. - The company grew its subscriber base from 391,000 in Q1 2021 to 1.7 million in Q1 2024, indicating strong growth in its overall business model, which includes various health and wellness products [9]. Group 2: Recent Developments - Novo Nordisk terminated its sales partnership with Hims & Hers due to the latter's continued sale of compounded semaglutide, which Novo Nordisk claims is an abuse of compounding practices to bypass patent protections [2][7]. - Hims & Hers began selling compounded semaglutide in May 2024, which contributed to its recent success, but the company was expected to cease this practice after the end of the semaglutide shortage in February [6][10]. Group 3: Allegations and Impact - Novo Nordisk has made serious allegations against Hims & Hers, including deceptive marketing practices and illegal mass compounding, which could potentially harm the company's brand and reputation [11][14]. - The company's management has provided sales guidance for 2025 of $2.3 billion to $2.4 billion, with approximately 30% of revenue expected from weight loss drugs, highlighting the importance of this segment to its overall business [10].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Hims & Hers Health, Inc. due to allegations of misleading statements and illegal practices that have led to significant investor losses [2][4]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses exceeding $50,000 in Hims between April 29, 2025, and June 22, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Hims, with a deadline of August 25, 2025, for investors to seek the role of lead plaintiff [2][6]. - The complaint alleges that Hims engaged in deceptive practices, including the promotion and sale of illegitimate versions of Wegovy®, which jeopardized patient safety [4]. Group 2: Partnership Termination and Stock Impact - On June 23, 2025, Novo Nordisk announced the termination of its partnership with Hims, citing violations of laws regarding the sale of compounded drugs and deceptive marketing practices [5]. - Following the announcement, Hims' stock price plummeted by $22.24, or 34.6%, closing at $41.98 per share, resulting in significant financial harm to investors [5]. Group 3: Call for Information - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding Hims' conduct to support the investigation [7].

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, primarily related to misleading statements and the promotion of illegitimate products, which led to a significant drop in stock price following the termination of a partnership with Novo Nordisk [1][2]. Company Overview - Hims & Hers is a telehealth company that offers prescription medications, over-the-counter medications, and personal care products [2]. - The company announced a collaboration with Novo Nordisk on April 29, 2025, to sell a bundled offering of Wegovy® [2]. Legal Allegations - The class action lawsuit alleges that Hims & Hers engaged in deceptive practices by promoting and selling illegitimate versions of Wegovy®, which jeopardized patient safety [2]. - Following the allegations, Novo Nordisk terminated its partnership with Hims & Hers on June 23, 2025, citing the deceptive practices as the reason [2]. - The lawsuit claims that the stock price of Hims & Hers fell by more than 34% after the announcement of the partnership termination [2]. Class Action Process - Investors who purchased Hims & Hers securities during the specified class period can seek to be appointed as lead plaintiff in the lawsuit [3]. - The lead plaintiff represents the interests of all class members and can select a law firm to litigate the case [3]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [4]. - The firm has a strong track record in obtaining significant recoveries in securities class action cases, including the largest recovery in history of $7.2 billion in the Enron case [4].

Core Viewpoint - Hims & Hers Health, Inc. is facing two securities class action lawsuits following the termination of its collaboration with Novo Nordisk due to concerns over deceptive marketing practices related to the weight loss drug Wegovy® [1][2][4]. Group 1: Lawsuits and Allegations - The lawsuits, filed in Northern California, seek to represent investors who acquired Hims & Hers securities between April 29, 2025, and June 23, 2025 [1][3]. - Allegations include that Hims & Hers made false and misleading statements and failed to disclose critical information regarding the safety and legality of its marketing practices [4][5]. - The complaints specifically mention that the company engaged in deceptive promotion and selling of knockoff versions of Wegovy®, which posed risks to patient safety and jeopardized its collaboration with Novo Nordisk [4][5]. Group 2: Impact of Novo Nordisk's Decision - Novo Nordisk announced the termination of its collaboration with Hims & Hers on June 23, 2025, citing concerns over illegal mass compounding and deceptive marketing practices [2][5]. - The announcement led to a significant 30% drop in the share price of Hims & Hers [2]. - Novo Nordisk emphasized that Hims & Hers failed to comply with legal standards regarding the sale of compounded drugs, which raised serious patient safety concerns [5]. Group 3: Investigation and Investor Actions - Hagens Berman, a national shareholders rights firm, is investigating the legal claims and encourages affected investors to report their losses [3][6]. - The firm is also seeking information from individuals who may assist in the investigation, highlighting the potential for whistleblower rewards under the SEC Whistleblower program [6].

Core Viewpoint - Hims & Hers Health, Inc. is under investigation for potential violations of federal securities laws following the termination of its partnership with Novo Nordisk due to allegations of deceptive marketing and safety risks associated with its products [1][3]. Group 1: Company Overview - Hims & Hers is a telehealth company that offers online consultations with licensed healthcare professionals, prescription medications, and wellness products [2]. - The company entered a "long-term collaboration" with Novo Nordisk to sell the weight loss drug Wegovy [2]. Group 2: Recent Developments - Novo Nordisk announced the termination of its partnership with Hims & Hers on June 23, 2025, citing accusations of "deceptive marketing" and the sale of illegitimate versions of Wegovy [3]. - Following the announcement, Hims & Hers' stock price dropped by $22.25 per share, a decline of over 34%, from $64.22 on June 20, 2025, to $41.97 on June 23, 2025 [3]. Group 3: Legal Implications - Bleichmar Fonti & Auld LLP is investigating Hims & Hers for potential legal actions related to the stock decline and allegations of misconduct [1][4]. - Investors in Hims & Hers are encouraged to seek legal options and submit their information to the law firm for potential representation [4]. Group 4: Law Firm Background - Bleichmar Fonti & Auld LLP is recognized as a leading international law firm specializing in securities class actions and shareholder litigation, with notable recoveries in past cases [5].

Core Viewpoint - Verb Technology Company, Inc. is leveraging its MARKET.live division to host an exclusive livestream shopping event for BelliWelli on Walmart.com, highlighting the growing trend of livestream shopping in retail [1][4]. Company Overview - Verb Technology Company, Inc. operates in social commerce, social telehealth, and social crowdfunding, utilizing its various platforms including MARKET.live, LyveCom, VANITYPrescribed, and GoodGirlRx [5][6]. - The company aims to transform the retail landscape by providing advanced AI capabilities for real-time user engagement and content creation, enhancing the shopping experience [6]. Event Details - The livestream event for BelliWelli will take place on July 1, 2025, at 4:00 PM PT, marking the brand's debut on Walmart.com [2]. - The event will be produced from MARKET.live Studios in California, ensuring a high-quality livestream shopping experience [2][3]. Industry Trends - Livestream shopping is becoming increasingly popular among major brands and retailers as a method to boost customer engagement and conversion rates, creating a more personalized shopping experience [4].

Company Overview - LifeMD (NASDAQ: LFMD) is a rapidly growing telehealth company that provides subscriptions and prescriptions for chronic conditions [1] - The company has 290,000 active patient subscribers and operates across all 50 states in the United States [1] Business Model - LifeMD's business model focuses on telehealth services, which include both subscription-based and prescription services [1] Market Position - LifeMD is positioned in the telehealth industry, which is experiencing significant growth due to increasing demand for remote healthcare solutions [1]

SAN DIEGO, June 25, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Hims & Hers Health, Inc. (NYSE: HIMS) securities between April 29, 2025 and June 23, 2025, inclusive (the “Class Period”), have until August 25, 2025 to seek appointment as lead plaintiff of the Hims & Hers class action lawsuit. Captioned Sookdeo v. Hims & Hers Health, Inc., No. 25-cv-05315 (N.D. Cal.), the Hims & Hers class action lawsuit charges Hims & Hers and certain of Hims & Hers’ to ...

Core Viewpoint - Hims & Hers Health, Inc. experienced a significant share price drop of over 30% following the termination of its collaboration with Novo Nordisk due to concerns regarding sales practices and marketing of the weight loss drug Wegovy® [1][4]. Company Summary - Hims & Hers Health, Inc. had previously partnered with Novo Nordisk to provide access to Wegovy®, which is FDA-approved for obesity treatment, through its platform [3]. - The partnership was short-lived, as Novo Nordisk cited "illegal mass compounding and deceptive marketing" as reasons for the termination [4]. - Hims & Hers had previously assured investors of its regulatory compliance, claiming it was not bypassing the regulatory process [2]. Investigation Summary - Hagens Berman, a national shareholders rights firm, has initiated an investigation into potential violations of securities laws by Hims & Hers, urging affected investors to report their losses [2]. - The investigation will focus on whether Hims & Hers misled investors regarding the marketing of potentially unsafe versions of Wegovy® [4].